Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/LSD/Implementation & Service Delivery

LSD for Implementation & Service Delivery

3 papers and 2 clinical trials exploring lsd as a treatment for implementation & service delivery.

Compoundclassic psychedelic

LSD

LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM120 have reignited clinical development.

Full LSD profile
IndicationApproximately 264 million people worldwide suffer from depression, while substance use disorders affect around 35 million globally.

Implementation & Service Delivery

This report explores the implementation and service delivery of psychedelic therapies, focusing on compounds such as psilocybin, MDMA, and LSD in various therapeutic contexts. Recent legislative efforts and clinical trials indicate a growing acknowledgement of the therapeutic potential of psychedelics, particularly in addressing mental health conditions and substance use disorders.

Full Implementation & Service Delivery profile

Academic Research

3 papers
Paywallindividual

The Canadian Psychedelic Survey: Characteristics, Patterns of Use, and Access in a Large Sample of People Who Use Psychedelic Drugs

This survey (n=2045) of Canadian psychedelic users finds psilocybin, MDMA and LSD are the most commonly used. It also reports positive (82%) life changes and challenging experiences (52%). Motivations for use include fun, self-exploration, general mental well-being, and personal growth.

Published
June 1, 2023
Journal
Psychedelic Medicine
Authors
Lake, S., Lucas, P.
Paywallindividual

Acute and enduring effects of naturalistic psychedelic use among Indigenous peoples in Canada and the United States

This survey study (n=66) explored the effects of naturalistic psychedelic use on recalled psychological distress and trauma symptoms among Indigenous peoples living in the United States and Canada who had experienced racial trauma. The most commonly used psychedelics were psilocybin, MDMA and LSD. Participants recalled experiencing fewer symptoms of depression, anxiety, stress, trauma, symptoms of discrimination, and alcohol use in the 30 days after (vs. before) the psychedelic experience

Published
November 1, 2022
Journal
Canadian Psychology
Authors
de la Salle, S., Gran-Ruaz, S., Davis, A. K., Davis, D., Williams, M. T.
Open Accessindividual

Socio-psychedelic imaginaries: envisioning and building legal psychedelic worlds in the United States

Based on three years of ethnographic research in the United States, this paper identifies and interprets four contemporary socio-psychedelic imaginaries — biomedicalization, decriminalization, legalization and sacramental — and analyses how they converge and diverge around politics of access, responsibility, naming, assimilation and epistemic credibility. It argues these co‑evolving imaginaries mutually shape and amplify one another, functioning as a societal corrective to decades of prohibition while rooted in human–psychedelic entanglements.

Published
April 30, 2022
Journal
European Journal of Futures Research
Authors
Schwarz-Plaschg, C.

Clinical Trials

2 trials
Not yet recruitingPhase II

A feasibility study of Psychedelic Microdosing-Assisted Meaning Centred Psychotherapy in advanced stage cancer patients (PAM Trial)

This double-blind, placebo-controlled feasibility trial (n=40) investigates Psychedelic Microdosing-Assisted Meaning-Centred Psychotherapy (PA–MCP) in advanced-stage cancer patients. Led by Dr Lisa Reynolds at The University of Auckland, the study evaluates LSD microdosing (starting at 8 µg, twice weekly for 6 weeks; 13 doses total) alongside Meaning-Centred Psychotherapy.

Started
June 1, 2023
Type
interventional
Blinding
single
Randomized
Yes
Registry ID
ACTRN12623000478617
Enrolling by invitationPhase NA

The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training (TherPsySE)

Single-group interventional study (n=48) assessing effects of personal psychedelic experience (MDMA, LSD, psilocybin) on therapists' therapeutic attitude and related capacities during SÄPT training.

Started
December 1, 2022
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT05570708

Explore further

Search all LSD papers Search all Implementation & Service Delivery trials Full LSD profile Full Implementation & Service Delivery profile